| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1999;99:2958-2963.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
Ganglionic Mechanisms Contribute to Diminished Vagal Control in Heart Failure
From the Department of Medicine–Cardiology, Veterans Affairs Medical Center and Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio.
Correspondence to Dr Mark E. Dunlap, MD, VA Medical Center Medical Research Service 151W, 10701 E Blvd, Cleveland, OH 44106. E-mail med3{at}po.cwru.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Previous work has shown that spontaneous and stimulated vagal activity is diminished in heart failure (HF) despite upregulation of functional postsynaptic cholinergic mechanisms. We therefore examined function of the postganglionic neuron in the paced canine model of HF as a possible site for diminished control.
Methods and Results—We measured sinus cycle length changes in response to electrical stimulation of preganglionic and postganglionic parasympathetic neurons innervating the sinoatrial node in control and HF dogs (both, n=8). Cervical vagus stimulation (preganglionic) demonstrated attenuated responses in the HF group at all levels of stimulation (P<0.05). Stimulation of the right atrial fat pad, containing both postganglionic nerves and terminals of preganglionic neurons, showed no such difference between control and HF (200±25 versus 192±18 ms). To ensure that preganglionic input and different levels of baseline sympathetic activity did not contribute to the group difference, similar stimulations were done in the presence of ganglionic and ß-adrenergic blockade. Under these conditions, postganglionic stimulation showed smaller changes in sinus cycle length, but the HF group response remained significantly higher than in controls (76±10 versus 20±2 ms; P<0.01), indicating that the difference was independent of preganglionic input and sympathetic activity.
Conclusions—A component of attenuated parasympathetic control in HF is located within the peripheral efferent limb. This defect is located within the parasympathetic ganglion. Future work should be focused on determining mechanisms of attenuated ganglionic transmission so that means targeted at restoring vagal activity can be developed.
Key Words: heart failure • vagus nerve • nervous system, autonomic • physiology
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Heart failure (HF) is characterized by significant changes in activity of the autonomic nervous system that are important in the pathophysiology of the disease. The sympathetic division is highly activated and is believed to contribute to the progression of the disease through direct effects on the myocardium as well as through activation of other neurohormonal systems such as the renin-angiotensin system.1 2 3 This pathophysiological role is highlighted by the use of pharmacological blockade of sympathetic nervous system–driven mechanisms (ACE inhibitors and ß-blockers) as the main approach to current therapy.4 5 Treatment with such pharmacological means is not ideal, however, because the responsible neurohumoral agents (norepinephrine and angiotensin II) have many and varied effects that are incompletely blocked by the actions of these agents.
In normal humans and animals, the parasympathetic nervous system has an important antagonistic effect on sympathetic activity and is essential for maintaining hemodynamic homeostasis. In addition to antagonizing sympathetic end-organ responses, parasympathetic activity modulates sympathetic drive at central and peripheral levels. The parasympathetic nervous system also may provide protection from arrhythmia and sudden death independently of sympathetic antagonism.6 However, control of the heart by the parasympathetic nervous system is attenuated in HF in both humans and animal models7 8 9 10 11 and is therefore unavailable to modulate increased sympathetic activity. The anatomic site(s) at which vagal control is reduced is unknown. Identification of the site(s) responsible for attenuated vagal control is important because it will provide insight into means of restoring activity in patients with HF and other conditions.
Previous work by this laboratory12 and
others13 has shown that postsynaptic mechanisms in the
heart are actually upregulated in an "intrinsic denervation
supersensitivity"–type manner in HF.14 15
M2 receptors in the sinus node are increased in
density, Gi
2 (the G-protein responsible for
cholinergic transduction in the heart) is increased,16 17 18
as is the mRNA for this protein,19 and these changes have
been confirmed to be functional in physiological
preparations.13 This has led us to investigate a defective
mechanism more proximal in the vagal cascade as a possible site for
diminished vagal control. Preliminary data from this laboratory in
isolated canine atria showed that 1,1-dimethyl-4-phenylpiperazinium
iodide (DMPP, a nicotinic agonist) produces a diminished response in
sinus cycle length (SCL) in HF dogs.20 To determine
whether this is due to mechanisms at the nicotinic receptor or
mechanisms distal to the ganglion, we conducted the present series
of experiments. The aim of the present report was to determine
whether a defect within the postganglionic neuron contributes to
diminished vagal control in HF.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Induction of HF
We have previously discussed the technique used for induction of HF.21 All procedures were carried out according to institutional guidelines for the care and use of laboratory animals. Young adult (9- to 12-month-old) male Beagle dogs were anesthetized with sodium pentothal and maintained with fluorothane gas. After the left external jugular vein had been exposed under sterile conditions, a Medtronic pacing wire was passed through the atrium and lodged in the apex of the right ventricle under fluoroscopic guidance. Pacing thresholds and resistances were determined to ensure adequate capture. The lead was then tunneled subcutaneously over the scapula and attached to a Medtronic pacemaker that was placed in a subcutaneous pocket behind the left shoulder. Dogs were kept on 250 mg cephradine BID for 3 days after surgery and allowed to recover for 7 to 10 days before the pacemaker was programmed at 250 bpm. The animals were checked daily by auscultation to ensure continued pacing. ECG strips were taken on a weekly basis or otherwise if there was suspicion of intermittent capture. Pacing was continued until the animal showed clinical signs of HF in 4 to 6 weeks. These signs included ascites, tachypnea, rales, decreased appetite, pallor with slowed capillary refill time in the gums, and dilatation of the ventricles on echocardiographic assessment.
Experimental Protocol
The experimental protocol was performed within a few days of
development of HF. The dogs were anesthetized with
-chloralose via an intravenous drip until toe pinch
reflex was absent. Supplemental chloralose was given the same way every
45 minutes. After endotracheal intubation, the dogs were placed on a
respirator (Harvard Apparatus) and were ventilated with
room air. A heating blanket maintained temperature in the
physiological range. The femoral artery and vein
were cannulated for continuous BP monitoring and drug administration. A
Swan-Ganz catheter was advanced to the pulmonary artery via the
right external jugular vein and connected to a cardiac output computer
(Edwards Laboratories) for determination of cardiac output.
The vagus nerves were dissected and isolated at the cervical level through a single midline incision. Each nerve trunk was ligated with heavy silk and then sectioned to prevent proximal conduction. Teflon-coated stainless steel wires were inserted into the proximal end of the caudal remnant of the right vagus nerve for stimulation. A right thoracotomy was made at the fourth intercostal space, and a pericardial cradle was formed. A bipolar electrode was then placed near the atrial appendage for recording of an electrogram. Two Teflon-coated wires were inserted into the pulmonary vein complex fat pad, a site that has been well documented as containing the ganglia of fibers innervating the sinus node area.22 23 24 This provided the means for direct electrical stimulation of postganglionic fibers.
Protocol
Vagus stimulations were performed at 3, 5, and 10 Hz at 8 V and
a pulse width of 1 ms. Atrial electrogram and ECG signals were
recorded for 15 seconds of baseline, 30 seconds of stimulation, and
15 seconds of recovery. Sufficient time was given between stimulations
to allow heart rate to return to prestimulation levels. To assess the
functional status of the postganglionic neuron, the fat pad was
stimulated by use of 2 different parameters. Subthreshold
stimulations were made at 3, 5, and 10 Hz at 8 V and a pulse width of
0.05 ms. These parameters were sufficient to
activate neurons within the tissue but not the
myocardium itself. Because postganglionic neurons are
unmyelinated and therefore more difficult to
activate electrically, subthreshold stimulations were used to
activate a combination of preganglionic fibers as well as some
postganglionic fibers innervating the sinoatrial node. To
activate postganglionic neurons in a more selective manner,
suprathreshold stimulations were performed at 8 V, 1 ms, and 200 Hz. To
avoid capturing the myocardium and affecting spontaneous
atrial electrical activity at these parameters, the
stimulator (Grass SD9) was configured to be triggered by the atrial
electrogram. This was achieved by passing the electrogram signal
through a conditioning stimulator (Grass S44), which created a pulse
that could be varied in duration and delivered during the atrial
refractory period. By altering the duration of the window, we
stimulated the fat pad with 1 to 5 pulses per atrial burst. Our
experience showed that 5 pulses provided the maximal response in most
of the dogs. Because these stimulations were at higher intensities,
they activated the unmyelinated postganglionic
fibers directly as well as activating preganglionic neurons.
To specifically isolate the postganglionic response to electrical stimulation, we induced ganglionic blockade with hexamethonium bromide 1 mg/kg IV and directly into the right atrial fat pad (2 to 5 mg). Blocking of ganglionic transmission would eliminate the effect of activating preganglionic neurons. This ensured that slowing of SCL was in response to stimulation of postganglionic neurons alone. Once blockade was achieved, the stimulation parameters were repeated as described above. Atropine (1 mg IV bolus) was given in some experiments to show that the SCL response to stimulation of the fat pad was abolished, confirming that the response was totally mediated by cholinergic mechanisms.
Because previous evidence has shown that direct electrical stimulation of the myocardium can activate intrinsic sympathetic neurons and sympathetic nerve endings,25 which could modify the vagal response, we sought to eliminate any ß-adrenergic effects. This was done after baseline stimulations with an infusion of esmolol HCl 200 µg/min, a short-acting ß-adrenergic blocker. The order in which each of these steps was implemented (hexamethonium or ß-blockade) was alternated in half of the experiments to evaluate the influence of ß-adrenergic signaling in postganglionic activation.
Data Capture and Analysis
ECG and electrogram signals were captured at 500 Hz with an
analog-to-digital converter (DATAQ Instruments) and stored on a 486 DX
PC. The signals were peak-detected (CODAS software, DATAQ Instruments)
and inspected to ensure appropriate electrogram detection. Point data
files were generated and the SCLs plotted graphically with Lotus 123.
Quantitative analysis of SCL was made with the specific data
points averaged over 10 seconds of baseline and during 15 seconds of a
30-second stimulation.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Hemodynamic Parameters
After an average of 5 weeks, paced dogs showed clear signs of HF. The Table
shows
hemodynamic parameters for each group
(mean±SD). Heart rate was generally higher in control dogs before and
after ß-blockade after bilateral vagotomy. Mean BP was lower in the
HF group, and mean capillary wedge pressure was doubled in HF dogs, as
expected. Cardiac output was markedly lower in HF dogs, and this
correlated well with ventricular dilatation calculated from
echocardiograms that were taken when clinical signs were evident. Group
differences for each parameter were significant at
P=0.01 except for heart rate (P=0.05).
|
Vagal Stimulation (Preganglionic)
Figure 1A shows an anatomic scheme
of vagal innervation and the points of stimulation (arrows) used in our
protocols. Figure 1B shows an individual SCL response to vagal
stimulation in both a control and an HF animal. Stimulation of the
cervical right vagus resulted in a prompt increase of SCL, and there
was no observable consistent difference in the rate of onset of
the effect between HF and control animals. As described by numerous
investigators,26 27 28 heart rate response to stimulation
faded over time; however, there appeared to be no difference between
control and HF in this respect (data not shown). Figure 2A illustrates the change in SCL (from
baseline) in response to vagal stimulation at the 3 levels for both
control and HF dogs. Slowing of SCL was greater at all levels of
stimulation in control animals (409±63, 572±93, and 1089±493 ms,
compared with 274±41, 430±61, and 995±166 ms in HF at 3, 5, and 10
Hz, respectively, P<0.05). Stimulation at 10 Hz caused
complete sinus arrest in 3 of the control dogs during stimulation, a
response not seen in any HF animal. To simplify data processing, these
responses were treated as a 10-second SCL. The difference between
controls and HF is therefore underrepresented in the
graph.
|
|
Subthreshold Stimulation
Stimulation at subthreshold levels, which stimulated predominantly
preganglionic neurons along with some postganglionic neurons (see
Methods), showed a pattern similar to vagal stimulation, that is, the
response was immediate and faded during stimulation. Figure 2B
shows group mean data for both control and HF subthreshold stimulation
at 3, 5, and 10 Hz. The degree to which SCL was increased was much less
than cervical vagal stimulation, and this did not change significantly
between different dogs in either group. Although no statistical
difference was found between control and HF animals
(P>0.05), control animals responded slightly more than HF
animals (97±35, 197±65, and 244±66 ms compared with 73±10, 113±20,
and 219±34 ms at 3, 5, and 10 Hz, respectively).
Suprathreshold Stimulation
Figure 3A shows group mean data for
control and HF dogs when suprathreshold stimulation of the fat pad was
used. Stimulation at all levels (1 to 5 pulses per atrial burst) shows
no significant difference in SCL response between the 2 groups:
119±17, 128±17, 163±18, 195±20, and 205±20 ms in controls compared
with 135±20, 151±18, 166±20, 179±20, and 192±10 ms in HF,
P>0.05. To completely isolate the postganglionic neuron, we
administered hexamethonium and repeated the highest
level of stimulation. Under ganglionic and adrenergic blockade (Figure 3B), the postganglionic response in the control animals (n=4)
was small (20±2 ms) compared with that in HF animals (n=6) (76±10 ms;
P<0.01), confirming that stimulation of the fat pad
previously was activating preganglionic neurons to a significant
degree. It also confirmed that the postganglionic mechanisms are
functional and more responsive in HF than in control animals.
|
Stimulations Under ß-Blockade
In 2 of the control dogs, we performed ganglionic blockade before
ß-adrenergic blockade. Stimulation of the fat pad under these
conditions produced tachycardia. Figure 4A shows an example of this response. The
response to stimulation was converted to bradycardia after
ß-adrenergic blockade, confirming that this was due to sympathetic
activation (4B). To ensure that this effect did not influence
the change in SCL induced by fat-pad stimulation, we conducted all 3
stimulation types under ß-blockade. Figure 5A shows the group mean data for vagal
stimulation before and after blockade. The ability to slow the heart
through vagal stimulation was greatly attenuated under ß-adrenergic
blockade (n=5, 409±63, 572±93, and 1896±493 ms compared with
131±36, 242±70, and 541±14 ms at 3, 5, and 10 Hz, respectively,
P<0.01). A similar effect was seen with suprathreshold
postganglionic stimulation (Figure 5B), although to a lesser
degree.
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Previous work in humans and animals has indicated that vagal control of the heart is diminished in HF. Eckberg et al7 published one of the earliest reports showing that parasympathetic control was reduced in patients with left ventricular dysfunction. They showed depressed chronotropic responses to atropine and impaired baroreflex control of heart rate in response to acute hypertension, suggesting attenuated vagal mechanisms. Porter et al8 confirmed that low (vagomimetic) doses of atropine, which induces vagal activity, did not elicit a change in heart rate in HF patients as it did in controls. They too concluded that vagal control was diminished in HF. A decrease of vagal control in HF also has been shown in the pacing-induced canine model of HF through spectral analysis.9 We have also shown previously in the canine paced model that vagal mechanisms are attenuated early in HF.11 Despite this information, the precise location(s) and mechanism(s) for abnormal vagal control are unknown.
Preganglionic Stimulation
In this study, we tested the functional capacity of the vagal
efferent limb by directly stimulating both preganglionic and
postganglionic neurons and monitoring end-organ (sinus node) responses.
Our data reveal that despite functional upregulation of cardiac
M2 receptors, preganglionic vagal stimulation
produces attenuated responses in HF dogs. This finding therefore
supports the notion that at least part of the vagal defect seen in HF
lies within the peripheral efferent limb. Anatomically,
this could be in preganglionic release of acetylcholine, acetylcholine
degradation dynamics, binding to the nicotinic receptor on the
postganglionic neuron, transduction and release of acetylcholine from
the postganglionic neuron, or acetylcholinesterase dynamics at the
neurocardiac synapse. Previous work by our laboratory has shown that
acetylcholinesterase is in fact downregulated in HF.29
This would theoretically increase the amount of acetylcholine in the
myocardium and thus potentiate the effects of the vagal
system. With present evidence indicating the anatomic location
responsible for attenuated vagal activity to be somewhere between the
preganglionic neuron and the synapse at the end organ, we investigated
the postganglionic neuron as a potential bottleneck in the vagal
cascade.
Postganglionic Stimulation
To test whether postganglionic mechanisms are functional in HF, we
stimulated postganglionic neurons innervating the sinoatrial node
directly and monitored changes in SCL. We found that stimulation of the
postganglionic neuron in HF elicits a functional response and has no
apparent functional abnormalities compared with controls. Thus, despite
an attenuation of vagal response during stimulation at the
preganglionic level, direct stimulation of the postganglionic neuron
produces responses equal to or greater than those seen in controls.
This clearly implies a role of the parasympathetic ganglion as a source
of diminished vagal activity seen in HF.
When the ganglion is stimulated directly (fat-pad stimulation), both preganglionic and postganglionic neurons are activated. Under normal conditions, preganglionic neurons contribute to a larger component of the excitation. The lack of statistical significance in our data before hexamethonium is reconciled by the fact that augmented postsynaptic mechanisms in the HF group are offset by greater ganglionic transmission in the control group. This concept is seen most strikingly in the prehexamethonium and posthexamethonium data for suprathreshold stimulation of the fat pad. Before ganglionic blockade, there was no significant difference between control and HF. After ganglionic blockade, however, the more effective ganglionic transmission in controls is removed, and there was a larger response in the HF group than in controls.
Stimulations After ß-Blockade
To examine whether stimulation of the fat pad also
activated sympathetic nerve terminals to release
epinephrine and whether this modified the response to vagal
stimulation, we performed the stimulations with and without
ß-adrenergic blockade. Figure 4A shows the SCL response to fat
pad stimulation with hexamethonium. After a rapid,
transient bradycardia (most likely initiated by rapid activation of
cholinergic mechanisms), there was a progressive
tachycardia in line with the slower dynamics of
ß-adrenergic signaling mechanisms. This response was transformed into
only bradycardia after ß-adrenergic blockade (Figure 4B),
indicating that the secondary tachycardia was mediated by
norepinephrine acting on ß-receptors. This supported the
notion that sympathetic stimulation could be attenuating the magnitude
of bradycardia in response to vagal postganglionic stimulation through
direct antagonism of signal transduction mechanisms (see below). As
shown in Figure 5A and 5B, with both preganglionic and
postganglionic stimulation, the response to vagal stimulation was
decreased in the presence of ß-blockade in control animals. The most
likely explanation for this is that a large component of vagal activity
on heart rate is dependent on a sympathetic substrate. This has been
described previously in detail by Levy,30 who coined the
term "accentuated antagonism." In this regard, although vagal
stimulation has direct effects on ion channels through binding of
acetylcholine and Gi2, much of its activity is
mediated via antagonizing the ß-adrenergic signaling pathway,
primarily through Gi2, which inhibits adenylyl
cyclase and the subsequent cAMP signaling effects. Alternatively, it is
possible that ß-adrenergic receptors may somehow augment the release
of acetylcholine; however, such a role has only been reported
previously for -receptors.31 32
These findings are important for understanding changes in vagal control so that we can target means to modulate its activity. Our report shows that in HF, the postganglionic neuron can release acetylcholine in sufficient quantities to create a response equal to or greater than that in controls. Although no interpretation regarding absolute release of acetylcholine can be made, the report shows that regardless of the amount of acetylcholine released, it can produce a normal response at the level of the sinus node in conjunction with upregulated postsynaptic mechanisms. This may be attributed to an adaptation of the postganglionic neuron itself, the downregulation of acetylcholinesterase, the previously reported upregulation in M2 receptors on the myocardium, or a combination of these factors.
Irrespective of the mechanisms that serve to normalize responses to postganglionic stimulation, the present data indicate that the parasympathetic ganglion is a primary site of defective transduction of vagal impulses in HF. Future work needs to be focused on determining the specific ganglionic mechanisms responsible, which may include release of acetylcholine from the preganglionic neuron into the ganglionic synapse or a change in ganglionic receptors. Because nicotinic receptors on ganglionic cells are ligand-gated ion channels, the diminished sensitivity would most likely involve changes in subtype or density of receptor rather than signal transduction mechanisms.
Limitations
As with all animal models that attempt to mimic human disease,
there is a possibility that this defect is unique to dogs. This seems
unlikely, because the neural and hormonal changes in the pacing model
very closely parallel those seen in humans with HF at both structural
and functional levels. In addition, we did not examine the possibility
that preganglionic mechanisms of the efferent limb are also defective.
Such an additional abnormality may add to the magnitude and
ramifications of a defective ganglion.
The implications of a defective ganglion in HF are significant. The magnitude of the defect is likely to be larger than that recorded in view of upregulated postsynaptic mechanisms and decreased degradation of acetylcholine at the synapse. It is possible that this defect may contribute significantly to the autonomic imbalance and high susceptibility to arrhythmia seen in HF patients. Furthermore, this finding may provide a new avenue for development of specific pharmacological intervention in the treatment of HF in the future.
|
Acknowledgments |
|---|
This work was supported by National Institutes of Health grant HL-50669 and the Department of Veterans Affairs. Mark Dunlap, MD, is a Clinical Investigator with the Department of Veterans Affairs. We thank Don Wallick, PhD, and Will Austin for their expert technical assistance. Special thanks to Rick Murtaugh from Medtronics Inc for his help with pacing equipment.
Received July 7, 1998; revision received March 9, 1999; accepted March 9, 1999.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Esler M, Kaye D, Lambert G, Esler D, Jennings G. Adrenergic nervous system in heart failure. Am J Cardiology. 1997;80:7L–14L.[Medline] [Order article via Infotrieve]
2.
Mulder P, Deveaux B, Richard V, Henry JP, Wimart MC,
Thibout E, Mace B, Thuillez C. Early versus delayed
angiotensin-converting enzyme inhibition in experimental
chronic heart failure: effects on survival,
hemodynamics, and cardiovascular
remodeling. Circulation. 1997;95:1314–1319.
3.
Sato N, Vatner SF, Shen YT, Kudej RK, Marzban BG,
Uechi M, Asai K, Mirsky I, Patrick TA, Shannon RP, Vatner DE. Effects
of cardiac denervation on development of heart failure and
catecholamine desensitization. Circulation. 1997;95:2130–2140.
4. The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685–691.[Abstract]
5.
Packer M, Bristow MR, Cohn JN, Collucci WS, Fowler MB,
Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure. N Engl
J Med. 1996;334:1349–1355.
6. De Ferrari GM, Salvati P, Grossoni M, Ukmar G, Vaga L, Patrono C, Schwartz PJ. Pharmacologic modulation of the autonomic nervous system in the prevention of sudden cardiac death. J Am Coll Cardiol. 1993;22:283–290.[Abstract]
7. Eckberg DL, Drabinsky M, Braunwald E. Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med. 1971;285:877–883.
8. Porter TR, Eckberg DL, Fritsch JM, Rea RF, Beightol JF, Schmedtje JF, Mohanty PK. Autonomic pathophysiology in heart failure patients: sympathetic-cholinergic interrelations. J Clin Invest. 1990;85:1362–1371.
9. Binkley PF, Nunziata E, Haas GJ, Nelson SD, Cody RJ. Parasympathetic withdrawal is an integral component of autonomic imbalance in congestive heart failure: demonstration in human subjects and verification in a paced canine model of ventricular failure. J Am Coll Cardiol. 1990;18:464–472.
10.
Sopher SM, Smith ML, Eckberg DL, Fritsch JM,
Dibner-Dunlap ME. Autonomic pathophysiology in heart failure: carotid
baroreceptor-cardiac reflexes. Am J Physiol. 1990;259:H689–H696.
11. Kinugawa T, Dibner-Dunlap ME. Altered vagal and sympathetic control of heart rate in left ventricular dysfunction and heart failure. Am J Physiol. 1995;268:R310–R316.
12. Kilani A, Dibner-Dunlap ME, Ernsberger P. Bidirectional site-specific alterations in muscarinic subtypes in heart failure. FASEB J. 1996;10:A691. Abstract.
13.
Vatner DE, Sato N, Galper JB, Vatner SF.
Physiological, biochemical evidence for coordinate
increase in muscarinic receptor and Gi during
pacing-induced heart failure. Circulation. 1996;94:102–107.
14. Hodges TD, Bailey JC, Fleming JW, Kovacs RJ. Selective parasympathectomy increases the quantity of inhibitory guanine nucleotide-binding proteins in canine cardiac ventricle. J Exp Ther Pharmacol. 1989;36:72–77.
15.
Kaseda S, Zipes DP. Supersensitivity to acetylcholine
of canine sinus and AV nodes after parasympathetic denervation.
Am J Physiol. 1988;255:H534–H539.
16.
Bohm M, Gierschick P, Jakobs KH, Pieske B, Schnabel P,
Ungerer M, Erdmann E. Increase of Gi in human
hearts with dilated but not ischemic
cardiomyopathy. Circulation. 1990;82:1249–1265.
17.
Marzo KP, Frey MJ, Wilson JR, Liang BT, Manning DR,
Lanoce V, Molinoff PB. ß- Adrenergic
receptor–G-protein–adenylate cyclase complex in
experimental canine congestive heart failure produced by rapid
ventricular pacing. Circ Res. 1991;69:1546–1556.
18. Feldman AM, Cates AE, Veazey W, Hershberger RE, Bristow MR, Baughman KL, Baumgartner WA, Van Dop C. Increase in the 40,000 mol. wt. pertussis toxin substrate (G-protein) in the failing human heart. J Clin Invest. 1988;82:189–197.
19.
Eschenhagen T, Mede U, Nose M, Schmitz W, Scholz H,
Haverich A, Hirt S, Doring V, Kalmar P, Hoppner W, Seitz HJ.
Increased messenger RNA level of the inhibitory G
protein subunit Gi-2 in human
end-stage heart failure. Circ Res. 1992;70:688–696.
20. Hussein FA, Dibner-Dunlap ME. The effect of ganglionic stimulation on intrinsic myocardial neural pathways in canines with and without heart failure. Circulation. 1996;94(suppl I):I-490. Abstract.
21. Dibner-Dunlap ME, Thames MD. A simplified technique for the production of heart failure in the dog by rapid ventricular pacing. Am J Med Sci. 1990;300:288–290.[Medline] [Order article via Infotrieve]
22.
Fee JD, Randall WC, Wurster RD, Ardell JL. Selective
ganglionic blockade of vagal inputs to sinoatrial and or
atrioventricular regions. J Pharmacol Exp
Ther. 1987;242:1006–1012.
23. Randall WC, Ardell JL, Wurster RD, Milosavljevic M. Vagal postganglionic innervation of the canine sinoatrial node. J Auton Nerv Syst. 1987;20:13–23.[Medline] [Order article via Infotrieve]
24.
Randall DC, Randall WC, Brown DR, Yingling JD, Raisch
RM. Heart rate control in awake dogs after selective SA-nodal
parasympathectomy. Am J Physiol. 1992;262:H1128–H1135.
25.
Furukawa Y, Wallick DW, Martin PJ, Levy MN.
Chronotropic and dromotropic responses to stimulation of intracardiac
sympathetic nerves to sinoatrial or atrioventricular
nodal region in anesthetized dogs. Circ Res. 1990;66:1391–1399.
26.
Furukawa Y, Levy MN. Temporal changes in the
sympathetic-parasympathetic interactions that occur in the perfused
canine atrium. Circ Res. 1994;55:835–841.
27. Martin P, Levy MN, Matsuda Y. Fade of cardiac responses during tonic vagal stimulation. Am J Physiol. 1982;243:H219–H225.
28. Jalife J, Hamilton AJ, Moe GK. Desensitization of the cholinergic receptor at the sinoatrial cell of the kitten. Am J Physiol. 1980;238:H439–H448.
29. Dibner-Dunlap ME, Lefton J, Rosenberry TL, Ernsberger P. Vagal control in heart failure: influence of muscarinic receptors and acetylcholinesterase activity. Circulation. 1992;86(suppl I):I-H.
30. Levy MN. Cardiac sympathetic-parasympathetic interactions. Fed Proc. 1984;43:2598–2602.[Medline] [Order article via Infotrieve]
31.
Wetzel GT, Goldstein D, Heller-Brown J. Acetylcholine
release from rat atria can be regulated through an
1-adrenergic receptor. Circ Res. 1985;56:763–766.
32. Wetzel GT, Heller-Brown J. Presynaptic modulation of acetylcholine release from cardiac parasympathetic neurons. Am J Physiol. 1985;248:H33–H39.
This article has been cited by other articles:
 |
|
 |
|
  Y. Zhang and T. N. Mazgalev Cardiac vagal stimulation eliminates detrimental tachycardia effects of dobutamine used for inotropic support. Ann. Thorac. Surg., July 1, 2009; 88(1): 117 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Schwartz, G. M. De Ferrari, A. Sanzo, M. Landolina, R. Rordorf, C. Raineri, C. Campana, M. Revera, N. Ajmone-Marsan, L. Tavazzi, et al. Long term vagal stimulation in patients with advanced heart failure First experience in man Eur J Heart Fail, September 1, 2008; 10(9): 884 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Olshansky, H. N. Sabbah, P. J. Hauptman, and W. S. Colucci Parasympathetic Nervous System and Heart Failure: Pathophysiology and Potential Implications for Therapy Circulation, August 19, 2008; 118(8): 863 - 871. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Freeling, K. Wattier, C. LaCroix, and Y.-F. Li Neostigmine and pilocarpine attenuated tumour necrosis factor {alpha} expression and cardiac hypertrophy in the heart with pressure overload Exp Physiol, January 1, 2008; 93(1): 75 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Monahan Effect of aging on baroreflex function in humans Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R3 - R12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. D. Watson, S. G. Hood, R. Ramchandra, R. M. McAllen, and C. N. May Increased cardiac sympathetic nerve activity in heart failure is not due to desensitization of the arterial baroreflex Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H798 - H804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.J. Akashi, G. Barbaro, T. Sakurai, K. Nakazawa, and F. Miyake Cardiac autonomic imbalance in patients with reversible ventricular dysfunction takotsubo cardiomyopathy QJM, June 1, 2007; 100(6): 335 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Rimmer and A. A. Harper Developmental Changes in Electrophysiological Properties and Synaptic Transmission in Rat Intracardiac Ganglion Neurons J Neurophysiol, June 1, 2006; 95(6): 3543 - 3552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E.J.F. Danson, Y.H. Zhang, C.E. Sears, A.R. Edwards, B. Casadei, and D.J. Paterson Disruption of inhibitory G-proteins mediates a reduction in atrial {beta}-adrenergic signaling by enhancing eNOS expression Cardiovasc Res, September 1, 2005; 67(4): 613 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bibevski and M. E. Dunlap Prevention of diminished parasympathetic control of the heart in experimental heart failure Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1780 - H1785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Miyamoto, T. Kawada, Y. Yanagiya, M. Inagaki, H. Takaki, M. Sugimachi, and K. Sunagawa Cardiac sympathetic nerve stimulation does not attenuate dynamic vagal control of heart rate via {alpha}-adrenergic mechanism Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H860 - H865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Arora, R. Cardinal, F. M. Smith, J. L. Ardell, L. J. Dell'Italia, and J. A. Armour Intrinsic cardiac nervous system in tachycardia induced heart failure Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2003; 285(5): R1212 - R1223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Dunlap, S. Bibevski, T. L. Rosenberry, and P. Ernsberger Mechanisms of altered vagal control in heart failure: influence of muscarinic receptors and acetylcholinesterase activity Am J Physiol Heart Circ Physiol, October 1, 2003; 285(4): H1632 - H1640. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.M. Mohan, D.A. Heaton, E.J.F. Danson, S.P.R. Krishnan, S. Cai, K.M. Channon, and D.J. Paterson Neuronal Nitric Oxide Synthase Gene Transfer Promotes Cardiac Vagal Gain of Function Circ. Res., December 13, 2002; 91(12): 1089 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Wallick, Y. Zhang, T. Tabata, S. Zhuang, K. A. Mowrey, J. Watanabe, N. L. Greenberg, R. A. Grimm, and T. N. Mazgalev Selective AV nodal vagal stimulation improves hemodynamics during acute atrial fibrillation in dogs Am J Physiol Heart Circ Physiol, October 1, 2001; 281(4): H1490 - H1497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. F. Notarius and J. S. Floras Limitations of the use of spectral analysis of heart rate variability for the estimation of cardiac sympathetic activity in heart failure Europace, January 1, 2001; 3(1): 29 - 38. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||